BioMarin Pharmaceuticals
BMRN
449 hedge funds and large institutions have $17.2B invested in BioMarin Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 167 increasing their positions, 138 reducing their positions, and 45 closing their positions.
56% more call options, than puts
Call options by funds: $180M | Put options by funds: $115M
47% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 45
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
21% more repeat investments, than reductions
Existing positions increased: 167 | Existing positions reduced: 138
18% more capital invested
Capital invested by funds: $14.6B → $17.2B (+$2.59B)
4% more funds holding
Funds holding: 430 → 449 (+19)
1.11% more ownership
Funds ownership: 102.41% → 103.52% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
+$197M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$140M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$138M |
| 4 |
SIG
Senator Investment Group
New York
|
+$87.6M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$178M |
| 2 |
O
OppenheimerFunds
New York
|
-$94.9M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$77.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$77.3M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$54.4M |
BMRN Hedge Fund Activity: Q2 2018 in Review
449 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2018, worth a combined $17.2B — up 18% from $14.6B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new BMRN positions and 45 closed out — a net gain of 21 holders — while 167 added to existing stakes and 138 trimmed.
The largest buyer was ClearBridge Investments, adding an estimated $197M. The largest seller was Fidelity Investments, cutting an estimated $178M.
- 449 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2018, up from 430 in Q1 2018.
- Funds reported $17.2B of BioMarin Pharmaceuticals stock for Q2 2018, up 18% quarter-over-quarter.
- 66 funds opened new BioMarin Pharmaceuticals positions in Q2 2018 and 45 closed out, a net change of +21 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2018 was ClearBridge Investments, an estimated $197M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2018 was Fidelity Investments, an estimated $178M sold.
Based on aggregated 13F filings for Q2 2018.